Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases

被引:5
|
作者
Werensteijn-Honingh, Anita M. [1 ]
Kroon, Petra S. [1 ]
Winkel, Dennis [1 ]
van Gaal, J. Carlijn [1 ]
Hes, Jochem [1 ]
Snoeren, Louk M. W. [1 ]
Timmer, Jaleesa K. [1 ]
Mout, Christiaan C. P. [1 ]
Bol, Gijsbert H. [1 ]
Kotte, Alexis N. [1 ]
Eppinga, Wietse S. C. [1 ]
Intven, Martijn [1 ]
Raaymakers, Bas W. [1 ]
Jurgenliemk-Schulz, Ina M. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Radiotherapy, HP Q00-3-11,POB 85500, NL-3508 GA Utrecht, Netherlands
关键词
Bowel; Duodenum; MR-linac; CBCT-linac; Stereotactic body radiotherapy; Lymph node metastases; RADIATION-THERAPY; ADAPTIVE RADIOTHERAPY; SBRT; FEASIBILITY; MOTION;
D O I
10.1016/j.phro.2022.06.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Magnetic resonance (MR)-linac delivery is expected to improve organ at risk (OAR) sparing. In this study, OAR doses were compared for online adaptive MR-linac treatments and conventional cone beam computed tomography (CBCT)-linac radiotherapy, taking into account differences in clinical workflows, especially longer session times for MR-linac delivery.Materials and methods: For 25 patients with pelvic/abdominal lymph node oligometastases, OAR doses were calculated for clinical pre-treatment and daily optimized 1.5 T MR-linac treatment plans (5 x 7 Gy) and compared with simulated CBCT-linac plans for the pre-treatment and online anatomical situation. Bowelbag and duodenum were re-contoured on MR-imaging acquired before, during and after each treatment session. OAR hard constraint violations, D0.5cc and D10cc values were evaluated, focusing on bowelbag and duodenum.Results: Overall, hard constraints for all OAR were violated less often in daily online MR-linac treatment plans compared with CBCT-linac: in 5% versus 22% of fractions, respectively. D0.5cc and D10cc values did not differ significantly. When taking treatment duration and intrafraction motion into account, estimated delivered doses to bowelbag and duodenum were lower with CBCT-linac if identical planning target volume (PTV) margins were used for both modalities. When reduced PTV margins were achievable with MR-linac treatment, bowelbag doses were lower compared with CBCT-linac. Conclusions: Compared with CBCT-linac treatments, the online adaptive MR-linac approach resulted in fewer hard planning constraint violations compared with single-plan CBCT-linac delivery. With respect to other bowelbag/duodenum dose-volume parameters, the longer duration of MR-linac treatment sessions negatively impacts the potential dosimetric benefit of daily adaptive treatment planning.
引用
收藏
页码:66 / 73
页数:8
相关论文
共 50 条
  • [41] Magnetic Resonance-guided stereotactic Radiotherapy for Patients with malignant Liver Neoplasms: First clinical Experience and Patient-Reported Outcome
    Weykamp, F.
    Klueter, S.
    Hoegen, P.
    Seidensaal, K.
    Koenig, L.
    Renkamp, K.
    Rippke, C.
    Regnery, S.
    Koerber, S.
    Buchele, C.
    Debus, J.
    Liermann, J.
    Horner-Rieber, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S65 - S65
  • [42] Impact of the Lorentz force on electron track structure and early DNA damage yields in magnetic resonance-guided radiotherapy
    Yachi, Yoshie
    Kai, Takeshi
    Matsuya, Yusuke
    Hirata, Yuho
    Yoshii, Yuji
    Date, Hiroyuki
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [43] Impact of the Lorentz force on electron track structure and early DNA damage yields in magnetic resonance-guided radiotherapy
    Yoshie Yachi
    Takeshi Kai
    Yusuke Matsuya
    Yuho Hirata
    Yuji Yoshii
    Hiroyuki Date
    Scientific Reports, 12 (1)
  • [44] Cost Effectiveness of Magnetic Resonance Imaging Guidance Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy
    Giuliani, Jacopo
    Mandara, Marta
    Fiorica, Francesco
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 634 - 635
  • [45] Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer: more than a simple "MIRAGE"?
    Bosetti, Davide Giovanni
    Angrisani, Antonio
    Castronovo, Francesco Mose
    Pesce, Gianfranco Angelo
    Zilli, Thomas
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (10) : 2454 - 2457
  • [46] PSA Kinetics and Outcomes after Magnetic Resonance Image-Guided Stereotactic Body Radiotherapy for Prostate Cancer
    Ugurluer, G.
    Mustafayev, T. Z.
    Atalar, B.
    Gungor, G.
    Sengoz, M.
    Abacioglu, M. U.
    Tuna, M. B.
    Kural, A. R.
    Ozyar, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E248 - E249
  • [47] Biologically Equivalent Dose Comparison Between Magnetic Resonance-Guided Adaptive and Computed Tomography-Guided Internal Target Volume-Based Stereotactic Body Radiotherapy for Liver Tumors
    Yoda, Kiyoshi
    Sato, Aya
    Miyake, Yuta
    Arato, Takeru
    Starbuck, William
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [48] 1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes
    Poon, Darren M. C.
    Yuan, Jing
    Wong, Oi-Lei
    Yang, Bin
    Chiu, Sin-Ting
    Cheung, Kin-Yin
    Chiu, George
    Yu, Siu-Ki
    CANCERS, 2021, 13 (19)
  • [49] Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer
    Ong, Wee Loon
    Hupman, M. Allan
    Davidson, Melanie
    Ruschin, Mark
    Detsky, Jay
    Liu, Stanley
    Vesprini, Danny
    Loblaw, Andrew
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 45
  • [50] Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial
    Ting Martin Ma
    James M. Lamb
    Maria Casado
    Xiaoyan Wang
    T. Vincent Basehart
    Yingli Yang
    Daniel Low
    Ke Sheng
    Nzhde Agazaryan
    Nicholas G. Nickols
    Minsong Cao
    Michael L. Steinberg
    Amar U. Kishan
    BMC Cancer, 21